July 30, 2012
Dainippon Sumitomo Pharma (DSP) and Nitto Denko Corporation announced on July 27 that they have initiated PII clinical studies for a transdermal patch formulation of the atypical antipsychotic Lonasen (blonanserin), which is being developed by the two companies. If commercialized,...read more